---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-064577"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T01:49:58.655287+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Relmada Q2 net loss narrows; Phase 3 MDD trials on track for 2024

## Summary
- Net loss $25.3M ($0.84/share) vs $39.9M ($1.33) in Q2 2022; R&D expense down to $13.7M from $30.9M.
- Cash and short-term investments $118.5M at June 30; company says sufficiently funded for Phase 3 readouts in 2024.
- Phase 3 Reliance II (302) enrollment ongoing; Relight (304) screening started; both expected to complete in 2024.
- One-year open-label safety study (Reliance-OLS) completed; data expected later in the current quarter.
- Human abuse potential data for REL-1017 published in peer-reviewed Translational Psychiatry.

## SEC filing metadata
- accession: 0001213900-23-064577
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390023064577/0001213900-23-064577-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390023064577/ea183083-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-064577
- JSON: https://secwatch.observer/filing/0001213900-23-064577.json
- Plain text: https://secwatch.observer/filing/0001213900-23-064577.txt

## Key facts
- Earnings Releases
  RELMADA THERAPEUTICS, INC. reported six months ended June 30, 2023 results: net income $51.6 million, EPS $1.72 per share.
  - Period: six months ended June 30, 2023
  - Net income: $51.6 million
  - EPS: $1.72 per share
  - Result: preliminary results
  source text: Net loss for the six months ended June 30, 2023 and 2022 was $51.6 million and $79.7 million, respectively. The Company had a net loss of $1.72 and $2.73 per share for the six months ended June 30, 2023 and 2022, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1553643/000121390023064577/0001213900-23-064577-index.htm
- Earnings Releases
  RELMADA THERAPEUTICS, INC. reported second quarter ended June 30, 2023 results: net income $25.3 million, or $0.84 per basic and diluted share, EPS $0.84 per basic and diluted share.
  - Period: second quarter ended June 30, 2023
  - Net income: $25.3 million, or $0.84 per basic and diluted share
  - EPS: $0.84 per basic and diluted share
  - Result: preliminary results
  source text: Net loss for the three months ended June 30, 2023, was $25.3 million, or $0.84 per basic and diluted share, compared with a net loss of $39.9 million, or $1.33 per basic and diluted share, for the three months ended June 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1553643/000121390023064577/0001213900-23-064577-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.